lithium compounds

Summary

Summary: Inorganic compounds that contain lithium as an integral part of the molecule.

Top Publications

  1. ncbi Evidence for association of an ACCN1 gene variant with response to lithium treatment in Sardinian patients with bipolar disorder
    Alessio Squassina
    Department of Neuroscience BB Brodie, University of Cagliari, Cagliari, Italy
    Pharmacogenomics 12:1559-69. 2011
  2. pmc Mania-like behavior induced by disruption of CLOCK
    Kole Roybal
    Department of Psychiatry and Center for Basic Neuroscience, University of Texas Southwestern Medical Center, Dallas, TX 75390 9070, USA
    Proc Natl Acad Sci U S A 104:6406-11. 2007
  3. pmc The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis
    Rodrigo Machado-Vieira
    Experimental Therapeutics, Mood and Anxiety Disorders Research Program, NIMH NIH, Department of Health and Human Services, Bethesda, MD 20892, USA
    Bipolar Disord 11:92-109. 2009
  4. ncbi Molecular effects of lithium
    Jorge A Quiroz
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, NIH, Bethesda, Maryland 20892, USA
    Mol Interv 4:259-72. 2004
  5. ncbi Hippocampal morphology in lithium and non-lithium-treated bipolar I disorder patients, non-bipolar co-twins, and control twins
    Theo G M van Erp
    Department of Psychiatry and Human Behavior, UCI, Irvine, California 92617, USA
    Hum Brain Mapp 33:501-10. 2012
  6. ncbi Early life stress changes concentrations of neuropeptide Y and corticotropin-releasing hormone in adult rat brain. Lithium treatment modifies these changes
    Henriette Husum
    Institution of Clinical Neuroscience and Institution of Physiology and Pharmacology, Division of Pharmacology, Karolinska Institutet, Stockholm, Sweden
    Neuropsychopharmacology 27:756-64. 2002
  7. pmc Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers
    Rulun Zhou
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Neuropsychopharmacology 34:1395-405. 2009
  8. ncbi Restraint stress influences AP-1 and CREB DNA-binding activity induced by chronic lithium treatment in the rat frontal cortex and hippocampus
    Jeannette C Miller
    Department of Psychiatry, New York University School of Medicine, New York, NY 10016 8382, USA
    Int J Neuropsychopharmacol 10:609-19. 2007
  9. ncbi A possible association between missense polymorphism of the breakpoint cluster region gene and lithium prophylaxis in bipolar disorder
    Takuya Masui
    Department of Psychiatry, Hokkaido University Graduate School of Medicine, Kita 15 Nishi 7, Kita ku, Sapporo, 060 8638, Hokkaido, Japan
    Prog Neuropsychopharmacol Biol Psychiatry 32:204-8. 2008
  10. ncbi The pharmacogenetics of lithium response depends upon clinical co-morbidity
    Troy Bremer
    Prediction Sciences, Inc, San Diego, California, USA
    Mol Diagn Ther 11:161-70. 2007

Research Grants

Detail Information

Publications222 found, 100 shown here

  1. ncbi Evidence for association of an ACCN1 gene variant with response to lithium treatment in Sardinian patients with bipolar disorder
    Alessio Squassina
    Department of Neuroscience BB Brodie, University of Cagliari, Cagliari, Italy
    Pharmacogenomics 12:1559-69. 2011
    ..Here, we present the results of an exploratory genome-wide scan followed by extended genotyping carried out on a sample of 204 Sardinian BD patients characterized for lithium response...
  2. pmc Mania-like behavior induced by disruption of CLOCK
    Kole Roybal
    Department of Psychiatry and Center for Basic Neuroscience, University of Texas Southwestern Medical Center, Dallas, TX 75390 9070, USA
    Proc Natl Acad Sci U S A 104:6406-11. 2007
    ..These findings establish the Clock mutant mice as a previously unrecognized model of human mania and reveal an important role for CLOCK in the dopaminergic system in regulating behavior and mood...
  3. pmc The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis
    Rodrigo Machado-Vieira
    Experimental Therapeutics, Mood and Anxiety Disorders Research Program, NIMH NIH, Department of Health and Human Services, Bethesda, MD 20892, USA
    Bipolar Disord 11:92-109. 2009
    ..Continued work to decipher lithium's molecular actions will likely lead to the development of not only improved therapeutics for BD, but to neurotrophic enhancers that could prove useful in the treatment of many other illnesses...
  4. ncbi Molecular effects of lithium
    Jorge A Quiroz
    Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, NIH, Bethesda, Maryland 20892, USA
    Mol Interv 4:259-72. 2004
    ..Many of the new insights of lithium's actions may lead to the strategic development of improved therapeutics for the treatment of bipolar disorder...
  5. ncbi Hippocampal morphology in lithium and non-lithium-treated bipolar I disorder patients, non-bipolar co-twins, and control twins
    Theo G M van Erp
    Department of Psychiatry and Human Behavior, UCI, Irvine, California 92617, USA
    Hum Brain Mapp 33:501-10. 2012
    ..We examined familial contributions to hippocampal morphology in bipolar disorder, using a population-based twin cohort design...
  6. ncbi Early life stress changes concentrations of neuropeptide Y and corticotropin-releasing hormone in adult rat brain. Lithium treatment modifies these changes
    Henriette Husum
    Institution of Clinical Neuroscience and Institution of Physiology and Pharmacology, Division of Pharmacology, Karolinska Institutet, Stockholm, Sweden
    Neuropsychopharmacology 27:756-64. 2002
    ..The results suggest that early life stress has long-term effects on brain NPY with implications for the development of depression/vulnerability to stress, and that one therapeutic mechanism of action of lithium is to increase brain NPY...
  7. pmc Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers
    Rulun Zhou
    Laboratory of Molecular Pathophysiology, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
    Neuropsychopharmacology 34:1395-405. 2009
    ..These findings are the first to demonstrate that miRNAs and their predicted effectors are targets for the action of psychotherapeutic drugs...
  8. ncbi Restraint stress influences AP-1 and CREB DNA-binding activity induced by chronic lithium treatment in the rat frontal cortex and hippocampus
    Jeannette C Miller
    Department of Psychiatry, New York University School of Medicine, New York, NY 10016 8382, USA
    Int J Neuropsychopharmacol 10:609-19. 2007
    ..Our findings of increased AP-1 and CREB binding after lithium are consistent with lithium's inhibitory effect on glycogen synthase kinase-3beta, which has been show to negatively regulate AP-1 and CREB transcriptional activity...
  9. ncbi A possible association between missense polymorphism of the breakpoint cluster region gene and lithium prophylaxis in bipolar disorder
    Takuya Masui
    Department of Psychiatry, Hokkaido University Graduate School of Medicine, Kita 15 Nishi 7, Kita ku, Sapporo, 060 8638, Hokkaido, Japan
    Prog Neuropsychopharmacol Biol Psychiatry 32:204-8. 2008
    ..We found that the allele frequency of Ser796 was significantly higher in non-responders than in responders. Further investigation is warranted to confirm our findings...
  10. ncbi The pharmacogenetics of lithium response depends upon clinical co-morbidity
    Troy Bremer
    Prediction Sciences, Inc, San Diego, California, USA
    Mol Diagn Ther 11:161-70. 2007
    ..A test that could predict response to lithium based upon genetic factors would have significant clinical value...
  11. pmc Lithium response and genetic variation in the CREB family of genes
    Firoza Mamdani
    McGill Group for Suicide Studies Depressive Disorders Group, Douglas Hospital, Research Centre, McGill University, Montreal, Quebec, Canada
    Am J Med Genet B Neuropsychiatr Genet 147:500-4. 2008
    ..Following correction for multiple testing, our results suggest that the CREB1-1H SNP (G/A change, P < 0.002) and the CREB1-7H SNP (T/C change, P < 0.002) may be associated with BD and/or lithium response...
  12. pmc The International Consortium on Lithium Genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment
    Thomas G Schulze
    Genetic Basis of Mood and Anxiety Disorders, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892 3719, USA
    Neuropsychobiology 62:72-8. 2010
    ..A stringent phenotype definition of response is one of the hallmarks of this collaboration. ConLiGen invites all lithium researchers to join its efforts...
  13. ncbi Paliperidone as a mood stabilizer: a pre-frontal cortex synaptoneurosomal proteomics comparison with lithium and valproic acid after chronic treatment reveals similarities in protein expression
    Maria del Pilar Corena-McLeod
    Neuropsychopharmacology Laboratory, Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA
    Brain Res 1233:8-19. 2008
    ....
  14. ncbi Pharmacogenetics of lithium long-term treatment: focus on initiation and adaptation mechanisms
    Alessandro Serretti
    Institute of Psychiatry, University of Bologna, Bologna, Italy
    Neuropsychobiology 62:61-71. 2010
    ..Moreover, the pharmacogenetics reports that are not strictly associated with the mechanisms that are thought to be acutely and chronically elicited by lithium will be included in the final part of the paper...
  15. ncbi Identifying predictors for good lithium response - a retrospective analysis of 100 patients with bipolar disorder using a life-charting method
    Lena Backlund
    Karolinska Institute, Department of Clinical Neuroscience, Section of Psychiatry, Karolinska University Hospital, Huddinge M57, SE 141 86 Stockholm, Sweden
    Eur Psychiatry 24:171-7. 2009
    ..Our aim was to investigate bipolar patients in order to test the validity of various outcome measures and to identify prognostic predictors for pharmacological treatment...
  16. pmc Effects of alcohol, lithium, and homocysteine on nonmuscle myosin-II in the mouse placenta and human trophoblasts
    Mingda Han
    Department of Pediatrics, University of South Florida All Children s Hospital Children s Research Institute, St Petersburg, FL, USA
    Am J Obstet Gynecol 207:140.e7-19. 2012
    ....
  17. ncbi No association of three GRIN2B polymorphisms with lithium response in bipolar patients
    Aleksandra Szczepankiewicz
    Psychiatric Genetics Unit, Department of Psychiatry, Poznan University of Medical Sciences, Poland
    Pharmacol Rep 61:448-52. 2009
    ..The authors conclude that polymorphisms of the GRIN2B gene did not show an association with the treatment response to lithium in bipolar patients...
  18. ncbi Lithium: still a cornerstone in the long-term treatment in bipolar disorder?
    Alessandra M A Nivoli
    Bipolar Disorder Program, IDIBAPS, CIBERSAM, Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, Barcelona, Spain
    Neuropsychobiology 62:27-35. 2010
    ..Despite its worldwide clinical use, the effectiveness of lithium has been questioned. The aim of this work is to critically review the available data on randomized controlled trials (RCTs) concerning long-term lithium treatment...
  19. ncbi Stargazin involvement with bipolar disorder and response to lithium treatment
    Gilad Silberberg
    Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Pharmacogenet Genomics 18:403-12. 2008
    ....
  20. ncbi Bipolar disorder
    R H Belmaker
    Stanley Research Center, Ben Gurion University of the Negev, Beersheba, Israel
    N Engl J Med 351:476-86. 2004
  21. ncbi Actimetric evidence that CLOCK 3111 T/C SNP influences sleep and activity patterns in patients affected by bipolar depression
    Francesco Benedetti
    Department of Neuropsychiatric Sciences, Scientific Institute and University Vita Salute San Raffaele, Milan, Italy
    Am J Med Genet B Neuropsychiatr Genet 144:631-5. 2007
    ..Individual characteristics of the molecular clock can influence sleep symptoms in mood disorders...
  22. ncbi Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial
    Laksami N Yatham
    University of British Columbia, Vancouver, Canada
    Br J Psychiatry 182:141-7. 2003
    ..Few double-blind trials have examined the efficacy of a combination of a mood stabiliser and an atypical antipsychotic in acute mania...
  23. ncbi Family-based association study of lithium-related and other candidate genes in bipolar disorder
    Roy H Perlis
    Psychiatric and Neurodevelopmental Genetics Unit, Center for Human Genetic Research, Massachusetts General Hospital, 185 Cambridge St, Boston, MA 02114, USA
    Arch Gen Psychiatry 65:53-61. 2008
    ..Recent developments suggest that a broader pool of genes may be associated with this disorder...
  24. pmc In search of the Holy Grail for the treatment of neurodegenerative disorders: has a simple cation been overlooked?
    De Maw Chuang
    Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892 1363, USA
    Biol Psychiatry 62:4-6. 2007
  25. ncbi Lithium reduces ischemia-induced hippocampal CA1 damage and behavioral deficits in gerbils
    Qingming Bian
    Department of Anesthesiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, PR China
    Brain Res 1184:270-6. 2007
    ..These results underscore the ability of lithium to improve functional behavioral outcome in gerbil and rodent cerebral ischemic models and further indicate the potential therapeutic use of lithium in certain human stroke conditions...
  26. pmc Lipopolysaccharide-induced interleukin-6 production is controlled by glycogen synthase kinase-3 and STAT3 in the brain
    Eleonore Beurel
    Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, AL 35294 0017, USA
    J Neuroinflammation 6:9. 2009
    ..To identify potential targets to control brain IL-6, we tested if IL-6 produced by glia is regulated by signal transducer and activator of transcription-3 (STAT3) and glycogen synthase kinase-3 (GSK3)...
  27. ncbi Interacting genes in lithium prophylaxis: preliminary results of an exploratory analysis on the role of DGKH and NR1D1 gene polymorphisms in 199 Sardinian bipolar patients
    Mirko Manchia
    Laboratory of Molecular Genetics, Department of Neurosciences B B Brodie, University of Cagliari, SS 554, Km 4, 500, 09042 Monserrato, Cagliari, Italy
    Neurosci Lett 467:67-71. 2009
    ..Moreover, the lack of statistic interaction might not necessarily correspond to a lack of biologic interaction between the genes studied...
  28. ncbi The PDLIM5 gene and lithium prophylaxis: an association and gene expression analysis in Sardinian patients with bipolar disorder
    Alessio Squassina
    Section of Clinical Pharmacology, Department of Neurosciences B B Brodie, University of Cagliari, SS 554, Km 4, 500, 09042 Monserrato, Cagliari, Italy
    Pharmacol Res 57:369-73. 2008
    ..Our negative findings do not exclude involvement of PDLIM5 in lithium prophylaxis, and further investigation is warranted...
  29. ncbi The role of lithium in modulation of brain genes: relevance for aetiology and treatment of bipolar disorder
    S Hossein Fatemi
    Department of Psychiatry, Division of Neuroscience Research, University of Minnesota Medical School, MMC 392, Minneapolis, MN 55455, USA
    Biochem Soc Trans 37:1090-5. 2009
    ....
  30. ncbi No association between lithium full responders and the DRD1, DRD2, DRD3, DAT1, 5-HTTLPR and HTR2A genes in a Sardinian sample
    Mirko Manchia
    Section of Clinical Pharmacology, Department of Neurosciences B B Brodie, University of Cagliari, P O San Giovanni di Dio, Via Ospedale 46, 09124 Cagliari, Italy
    Psychiatry Res 169:164-6. 2009
    ..No significant association was shown between the polymorphisms of the genes studied and response to lithium treatment...
  31. ncbi Akt/GSK3 signaling in the action of psychotropic drugs
    Jean Martin Beaulieu
    Department of Anatomy and Physiology, Université Laval CRULRG, Quebec, Canada
    Annu Rev Pharmacol Toxicol 49:327-47. 2009
    ..Elucidation of the contribution of multiple signaling pathways to the action of psychotropic drugs may provide a better biological understanding of psychiatric disorders and lead to more efficient therapeutics...
  32. ncbi Neuroprotective effect of chronic lithium treatment against hypoxia in specific brain regions with upregulation of cAMP response element binding protein and brain-derived neurotrophic factor but not nerve growth factor: comparison with acute lithium treat
    N Omata
    Department of Neuropsychiatry, University of Fukui, Fukui, Japan
    Bipolar Disord 10:360-8. 2008
    ..Furthermore, we investigated the contribution of brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and cAMP response element binding protein (CREB) to the neuroprotective effect of lithium...
  33. ncbi A double blind, randomized, placebo-controlled trial of quetiapine as an add-on therapy to lithium or divalproex for the treatment of bipolar mania
    Lakshmi N Yatham
    Division of Mood Disorders, University of British Columbia, UBC Hospital, Vancouver, British Columbia, Canada
    Int Clin Psychopharmacol 22:212-20. 2007
    ..Overall, the combination of quetiapine with lithium or divalproex was well tolerated...
  34. ncbi Lithium reduces pathological aggression and suicidality: a mini-review
    Bruno Muller-Oerlinghausen
    Drug Commission of the German Medical Association, Berlin, Germany bmoe zedat fu berlin de
    Neuropsychobiology 62:43-9. 2010
    ....
  35. ncbi Risperidone plus lithium versus risperidone plus valproate in acute and continuation treatment of mania
    Lakshmi N Yatham
    University of British Columbia, Vancouver, British Columbia Janssen Ortho Inc, Toronto, Canada
    Int Clin Psychopharmacol 19:103-9. 2004
    ..These data suggest that risperidone can be safely combined with either lithium or valproate, and that the efficacy is similar regardless of the mood stabilizer used...
  36. ncbi Monitoring of glomerular filtration rate in lithium-treated outpatients--an ambulatory laboratory database surveillance
    Nader Bassilios
    Réseau Néphropar and Nephrology Department, AP HP, Necker Hospital, Paris, France
    Nephrol Dial Transplant 23:562-5. 2008
    ..The long-term risk of chronic kidney disease (CKD) in lithium (Li)-treated patients has been well established in the recent years...
  37. ncbi Lithium: a review of its metabolic adverse effects
    Callum Livingstone
    Clinical Biochemistry Department, Royal Surrey County Hospital, Guildford, Surrey, UK
    J Psychopharmacol 20:347-55. 2006
    ..We review aspects of these actions of lithium including their prevalence, risk factors, biochemical changes involved and management, and discuss some advances that have been made in their understanding in recent years...
  38. pmc Lithium delays progression of amyotrophic lateral sclerosis
    Francesco Fornai
    Department of Human Morphology and Applied Biology, University of Pisa 56100 Pisa, Italy
    Proc Natl Acad Sci U S A 105:2052-7. 2008
    ..All these mechanisms may contribute to the effects of lithium, and these results offer a promising perspective for the treatment of human patients affected by ALS...
  39. ncbi Calpains as a target for therapy of neurodegenerative diseases: putative role of lithium
    Antoni Camins
    Institut de Biomedicina, Centros de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, Universitat de Barcelona Nucli Universitari de Pedralbes, Barcelona, Spain
    Curr Drug Metab 10:433-47. 2009
    ....
  40. ncbi Evolving trends in the long-term treatment of bipolar disorder
    Eduard Vieta
    Bipolar Disorders Program, Hospital Clinic, University of Barcelona, IDIBAPS, Barcelona, Spain
    World J Biol Psychiatry 8:4-11. 2007
    ..The role of psychoeducation in improving adherence to medication in long-term treatment and overall patient outcomes is also crucial...
  41. pmc Validating GSK3 as an in vivo target of lithium action
    W Timothy O'Brien
    Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Biochem Soc Trans 37:1133-8. 2009
    ..These observations, from several independent laboratories, support a central role for GSK3 in mediating behavioural responses to lithium...
  42. ncbi Implications of the neuroprotective effects of lithium for the treatment of bipolar and neurodegenerative disorders
    M Bauer
    Department of Psychiatry and Psychotherapy, Charite University Medicine Berlin, Campus Charité Mitte CCM, Berlin, Germany
    Pharmacopsychiatry 36:S250-4. 2003
    ..We propose to examine the effect of long-term lithium treatment on neurocognitive functioning of bipolar patients and the use of lithium in the treatment of chronic neuropsychiatric disorders...
  43. ncbi Suicide risk in bipolar disorder during treatment with lithium and divalproex
    Frederick K Goodwin
    Department of Psychiatry, George Washington University Medical Center, Washington, DC 20037, USA
    JAMA 290:1467-73. 2003
    ....
  44. ncbi Intracellular pathways underlying the effects of lithium
    Livia Pasquali
    Department of Neuroscience, University of Pisa, Pisa, Italy
    Behav Pharmacol 21:473-92. 2010
    ..This review is an attempt to elucidate the primary effects of lithium to interconnect the simpler targets to the most complex pharmacological effects...
  45. ncbi Toxicity of lithium to humans and the environment--a literature review
    Hal Aral
    CSIRO Minerals, Box 312, Clayton South, VIC 3169, Australia
    Ecotoxicol Environ Saf 70:349-56. 2008
    ..At 15 mg/L they experience confusion and speech impairment, and at 20 mg/L Li there is a risk of death. A provisional recommended daily intake of 14.3 microg/kg body weight lithium for an adult has been suggested...
  46. ncbi Lithium in bipolar and other affective disorders: prescribing practice in the UK
    Carol Paton
    Centre for Mental Health, Imperial College Faculty of Medicine, Charing Cross Campus, St Dunstan s Road, London, UK
    J Psychopharmacol 24:1739-46. 2010
    ..A significant minority of patients prescribed lithium had a sub-therapeutic blood level and so may be at high risk of relapse...
  47. ncbi Clinical features, polysomnography and outcome in patients with hypnic headache
    J F Liang
    Department of Neurology, National Yang Ming University School of Medicine, Taipei, Taiwan
    Cephalalgia 28:209-15. 2008
    ..The major reason was the presence of pulsatile rather than dull headache in our patients. Unlike previous studies, our study showed hypnic headache occurred equally in both REM and non-REM sleep, and most patients ran an episodic course...
  48. ncbi A critical appraisal of lithium's efficacy and effectiveness: the last 60 years
    Paul Grof
    Mood Disorders Center of Ottawa, Ottawa
    Bipolar Disord 11:10-9. 2009
    ..More recently, lithium has also proven to dramatically reduce suicidal behavior and mortality and to augment markedly the efficacy of antidepressants in unresponsive patients...
  49. ncbi Risperidone in acute and continuation treatment of mania
    Lakshmi N Yatham
    Department of Psychiatry, University of British Columbia, Vancouver, Canada
    Int Clin Psychopharmacol 18:227-35. 2003
    ..Risperidone add-on does not induce depressive symptoms and, furthermore, risperidone may have efficacy in treating comorbid depressive symptoms in bipolar patients...
  50. ncbi Theoretical and experimental investigation of the f(D)max-(S/S0)max anomaly in LiF:Mg,Ti
    S Biderman
    Crystals Department, Nuclear Research Center Negev, Beer Sheva 84190, Israel
    Radiat Prot Dosimetry 119:289-92. 2006
    ..Allowing N(LC) to increase as the sensitisation dose is increased, a good fit to both f(D) and S(Ds)/S0 is obtained...
  51. ncbi Neutron dosimetry with 6LiF-rich TL sheet
    Akiko Konnai
    National Maritime Research Institute, Mitaka, Tokyo 181 0004, Japan
    Radiat Prot Dosimetry 120:133-5. 2006
    ..The experimental measurements are shown to be in good agreement with the calculations...
  52. ncbi Modelling the dose response of peaks 4, 5 and 5b, in TLD-100, as a function of recombination temperature
    S Biderman
    Crystals Department, Nuclear Reasearch Center Negev, Beer Sheva 84190, Israel
    Radiat Prot Dosimetry 119:285-8. 2006
    ....
  53. ncbi Search for ionisation density effects in the radiation absorption stage in LiF:Mg,Ti
    I Nail
    Physics Department, Ben Gurion University of the Negev, Beersheva 84105, Israel
    Radiat Prot Dosimetry 119:180-3. 2006
    ....
  54. ncbi Response of LiF:Mg,Ti to low energy carbon and oxygen ions
    M Rodriguez-Villafuerte
    Instituto de Fisica, UNAM, A P 20 364, 01000 México DF, Mexico
    Radiat Prot Dosimetry 119:106-10. 2006
    ..Data for peak 5 show a weak dependence with energy. These latter results are difficult to understand when one considers the differences in the expected radial occupancies for different ion energies...
  55. ncbi Time-resolved spectroscopy of LiF:Mg,Cu,P
    V K Mathur
    Naval Surface Warfare Center, Carderock Division, 9500 MacArthur Boulevard, Bethesda, MD 20817, USA
    Radiat Prot Dosimetry 119:143-7. 2006
    ..Possible explanations for the observed emission spectra are discussed in this paper...
  56. ncbi Thermoluminescence emission spectra for the LiF:Mg,Cu,Na,Si thermoluminescent materials with various concentrations of the dopants (3-D measurement)
    J I Lee
    Health Physics Department, Korea Atomic Energy Research Institute, P O Box 105, Yuseong, Daejeon, Korea
    Radiat Prot Dosimetry 119:293-9. 2006
    ..However, any change in the wavelength at a main peak of the TL emission spectra from the sample materials with Na and Si dopants is not observed but that in the intensity at a peak of the spectra is observed...
  57. ncbi Comparison of two extremity dosemeters based on LiF:Mg,Cu,P thin detectors for mixed beta-gamma fields
    M Ginjaume
    Institute of Energy Technology INTE, Technical University of Catalonia UPC, Diagonal 647, 08028 Barcelona, Spain
    Radiat Prot Dosimetry 120:316-20. 2006
    ..However, the results also highlight a large variability among the different thin detectors and, thus, the standard TLD-100 material is recommended whenever the workplace does not include low-energy beta radiation...
  58. ncbi Comparative study of LiF:Mg,Cu,Na,Si and Li2B4O7:Cu,Ag,P TL detectors
    S Miljanic
    Ruder Boskovic Institute, Bijenicka 54, 10000 Zagreb, Croatia
    Radiat Prot Dosimetry 119:191-6. 2006
    ..The most important is the five times higher sensitivity than that of TLD-100. This detector is also very promising, especially in medical dosimetry...
  59. ncbi Dosimetry of densely ionising radiation with three LiF phosphors for space applications
    P Bilski
    Institute of Nuclear Physics, Radzikowskiego 152, 31 342 Krakow, Poland
    Radiat Prot Dosimetry 120:397-400. 2006
    ..The proposed method will be applied for analysis of several thousand TLDs used for the determination of organ doses in an anthropomorphic phantom orbiting outside the International Space Station within the MATROSHKA experiment...
  60. ncbi Comments on 'Observation of enhanced efficiency in the excitation of ion-induced LiF:Mg,Ti thermoluminescent peaks' G. Massillon., I. Gamboa-deBuen and M.E. Brandan, J. Appl. Phys. 100, 103521-1 (2006)
    Y S Horowitz
    Radiat Prot Dosimetry 124:411-6; author reply 417-9. 2007
  61. ncbi Properties of the 4.45 eV optical absorption band in LiF:Mg,Ti
    I Nail
    Physics Department, Ben Gurion University of the Negev, Beer Sheva 84105, Israel
    Radiat Prot Dosimetry 119:244-7. 2006
    ..Its presence in optical grade single crystal LiF further suggests that it is an intrinsic defect or possibly associated with chance impurities other than Mg, Ti...
  62. ncbi Characterisation of thermoluminescent LiF:Mg,Ti (MTS-N) detectors in the 85-550 K temperature range
    D Briand
    LPES CRESA, EA1174, Universite de Nice Sophia Antipolis, France
    Radiat Prot Dosimetry 100:297-300. 2002
    ..TSEE glow curves above 300 K similar to those of TL were observed. The behaviour of TSEE and TL peak 5 following an X ray exposure from 33 to 500 Gy was studied: its intensity is a linear function of air kerma in both cases...
  63. ncbi LiF:Mg,Ti TLD response as a function of photon energy for moderately filtered x-ray spectra in the range of 20-250 kVp relative to 60Co
    A A Nunn
    Department of Medical Physics, University of Wisconsin, Madison, Wisconsin 53706, USA
    Med Phys 35:1859-69. 2008
    ..Radiat. Prot. Dosim. 106, 33-43 (2003)]. This is likely due to complications in the solid state physics of the thermoluminescence process that are not incorporated into the simulation...
  64. ncbi Study of real time temperature profiles in routine TLD read out--influences of detector thickness and heating rate on glow curve shape
    H Stadtmann
    ARC Seibesdorf Research GmbH, A 2444 Seibesdorf, Austria
    Radiat Prot Dosimetry 119:310-3. 2006
    ..On the basis of this work, an optimisation of the readout parameters for LiF:Cu,P is possible...
  65. ncbi Miniature LiF:Mg,Cu,P TLDs to study the effect of applicator material in 192-Ir brachytherapy
    C Hood
    University of Newcastle, Division of Physics, Callaghan NSW 2038, Australia
    Australas Phys Eng Sci Med 29:300-2. 2006
    ..Computerized treatment planning (Philips/ADAC Pinnacle) was in good agreement with the measured data...
  66. ncbi Low temperature radioluminescence of LiF:Mg,Cu,P
    K Kurt
    Department of Physics, Faculty of Art and Science, University of Mersin 33343tr, Turkey
    Radiat Prot Dosimetry 119:134-8. 2006
    ..The role of donor acceptor pairs and the perturbations from intrinsic defects formed by ionisation can be used to describe all the observations. The 290 nm emission band is linked to H center annealing...
  67. ncbi On neutron-gamma mixed field dosimetry with LiF:Mg,Ti at radiation protection dose levels
    M Weinstein
    Ben Gurion University of the Negev, Beer Sheva, 84105, Israel
    Radiat Prot Dosimetry 119:314-8. 2006
    ..The Region of Interest method was used to define the areas of the Peaks 4 + 5 and 6 + 7. We found that a simple algorithm can be used to determine with good accuracy the separate contributions of neutron and gamma doses...
  68. ncbi Comparison of the energy-response factor of LiF and Al2O3 in radiotherapy beams
    Paul Mobit
    Medical Physics Department and Oncology Tom Baker Cancer Centre, 1331 29 Street N W, Calgary, Alberta, Canada T2N 4N2
    Radiat Prot Dosimetry 119:497-9. 2006
    ..19 for 250 kV X rays. The results show that the addition of 0.1 or 1% of carbon by weight (as dopant) into the Al2O3 does not change the Monte Carlo determined energy-response factor by more than 1%...
  69. ncbi Determination of LiF:Mg,Ti and LiF:Mg,Cu,P TL efficiency for X-rays and their application to Monte Carlo simulations of dosemeter response
    C Hranitzky
    ARC Seibersdorf Research GmbH, Health Physics Division, 2444 Seibersdorf, Austria
    Radiat Prot Dosimetry 119:483-6. 2006
    ..The concluding verification experiment showed small deviations between measured and simulated dosemeter energy response values in the range of a few percent...
  70. ncbi Energy responses of the LiF series TL pellets to high-energy photons in the energy range from 1.25 to 21 MV
    J L Kim
    Health Physics Department, Korea Atomic Energy Research Institute, Daejeon, Korea
    Radiat Prot Dosimetry 119:353-6. 2006
    ..For an application of these results to verify the therapy beams, an appropriate energy correction factor should be applied to the energies and phantom types in use...
  71. ncbi Thermoluminescence properties of LiF:Mg,Cu,Na,Si pellets in radiation dosimetry
    Y M Nam
    Radiat Prot Dosimetry 100:467-70. 2002
    ..Therefore LiF:Mg,Cu,Na,Si TL pellets can be used for personal dosimetry, but more research is needed to improve the characteristics for repeated use...
  72. ncbi CVD diamonds as thermoluminescent detectors for medical applications
    B Marczewska
    Institute of Nuclear Physics, Krakow, Poland
    Radiat Prot Dosimetry 101:485-8. 2002
    ..Due to the sensitivity of diamond to ambient light, it was difficult to achieve reproducibility comparable with that of standard LiF detectors...
  73. ncbi The unified interaction model applied to LiF:Mg,Ti (TLD-100): properties of the luminescent and competitive centres during sensitisation
    I Nail
    Physics Department, Ben Gurion University Beersheva, Israel
    Radiat Prot Dosimetry 102:295-304. 2002
    ....
  74. ncbi On the correct measurement of relative heavy charged particles to gamma thermoluminescent efficiencies
    O Avila
    Instituto Nacional de Investigaciones Nucleares, DF, Mexico
    Radiat Prot Dosimetry 100:87-90. 2002
    ....
  75. ncbi The TL fluence response to heavy charged particles using the track interaction model and track structure information
    M Rodriguez-Villafuerte
    Instituto de Fisica, UNAM, Mexico, Mexico
    Radiat Prot Dosimetry 100:99-102. 2002
    ..In spite of this, good agreement between the simulated TL-fluence response calculated for the 6.8 MeV 4He radial distributions and the experimental data for the two energies was achieved...
  76. ncbi Low temperature studies in LiF:Mg,Cu,P
    V K Mathur
    Naval Surface Warfare Center, Carderock Division, Bethesda, MD 20817, USA
    Radiat Prot Dosimetry 100:103-6. 2002
    ..On the basis of the present investigations it is proposed that the complex nature of the emission may be related to the formation of donor-acceptor pairs in this material. The possible nature of this donor-acceptor complex is discussed...
  77. ncbi Optical absorption and sensitisation dose response in LiF:Mg,Ti: application to the unified interaction model predictions of thermoluminescence dose response
    N Issa
    Physics Department, Ben Gurion University of the Negev, Beersheva, Israel
    Radiat Prot Dosimetry 100:107-10. 2002
    ....
  78. ncbi Developments in the synthesis of LiF:Mg,Cu,Na,Si TL material
    J I Lee
    Health Physics Department, Korea Atomic Energy Research Institute, P O Box 105, Taejon, Korea
    Radiat Prot Dosimetry 108:79-83. 2004
    ..Reusability study of the detector was carried out for 10 cycles. The results show that the coefficients of variation for each detector separately did not exceed 0.016, and that for all 10 detectors collectively was 0.0054...
  79. ncbi Microdosimetric interpretation of the photon energy response of LiF:Mg,Ti detectors
    P Olko
    Institute of Nuclear Physics, Krakow, Poland
    Radiat Prot Dosimetry 100:119-22. 2002
    ..The calculation procedure can be applied to predict the photon energy response of LiF:Mg,Ti detectors in an arbitrary photon field...
  80. ncbi The composite structure of peak 5 in the glow curve of LiF:Mg,Ti (TLD-100): confirmation of peak 5a arising from a locally trapped electron-hole configuration
    Y S Horowitz
    Radiat Prot Dosimetry 100:123-6. 2002
    ..iv) The low value of 0.1 for the 'track-escape' parameter of peak 5a deduced from the Extended Track Interaction Model analysis of He ion TL fluence response compared to order of magnitude greater values for peaks 5 and 5b...
  81. ncbi Localised and delocalised optically induced conversion of composite glow peak 5 in LiF:Mg,Ti (TLD-100) to glow peak 4 as a function of postirradiation annealing temperature
    Y S Horowitz
    Physics Department, Ben Gurion University of the Negev, Beersheva, Israel
    Radiat Prot Dosimetry 100:135-8. 2002
    ..The conduction/valence band competitive processes lead to the factor of one thousand decrease in the conversion efficiency of peak 5 compared to peak 5a...
  82. ncbi Lithium fluoride: from LiF:Mg,Ti to LiF:Mg,Cu,P
    P Bilski
    Institute of Nuclear Physics, Krakow, Poland
    Radiat Prot Dosimetry 100:199-206. 2002
    ..It is suggested that Ti hampers the acceptance of any increased amount of Mg into more traps in LiF:MgTi. The absence of Ti, not the presence of P or Cu, is therefore a key to the high sensitivity of LiF:MgCuP...
  83. ncbi A new high sensitivity thermoluminescent phosphor with low residual signal and good stability to heat treatment: LiF:Mg,Cu,Na,Si
    K Tang
    Solid Dosimetric Detector and Method Laboratory, Beijing, PR China
    Radiat Prot Dosimetry 100:239-42. 2002
    ..It retains the main advantages of LiF:Mg,Cu,P phosphor, and has a lower residual signal and a better stability to heat treatment...
  84. ncbi Role of impurities in the thermoluminescence of LiF:Mg,Cu,P
    T C Chen
    Department of Electrical Engineering, University of Washington, Seattle 98195, USA
    Radiat Prot Dosimetry 100:243-6. 2002
    ..It is also shown that a high content of oxygen in the material and control of the oxygen content during processing are critical to maintaining the sensitivity of these phosphors...
  85. ncbi Comparative study of trapping parameters and repeatability of LiF:Mg,Cu,P (GR-200A) from different production batches
    K Tang
    Solid Dosimetric Detector and Method Laboratory, Beijing, PR China
    Radiat Prot Dosimetry 100:345-8. 2002
    ..The peak areas of glow peaks 3 and 4 originating from 4 batches prepared during 1996 to 2000 are significantly larger than that of the other three batches. The GR-200A LiF:Mg,Cu,P has been improved dramatically in recent years...
  86. ncbi New advances in LiF:Mg,Cu,P TLDs (GR-200A)
    W Shen
    Solid Dosimetric Detector and Method Laboratory, Beijing, PR China
    Radiat Prot Dosimetry 100:357-60. 2002
    ..The uncertainty in low dose measurements is reduced significantly. The resistance to humidity has been improved remarkably. The preparation technology to volume-produce GR-200A is stable...
  87. ncbi Investigation of the emission spectra of LiF:Mg,Ti (TLD-100) during thermoluminescence
    S Biderman
    Physics Department, Ben Gurion University, Beer Sheva, 84105, Israel
    Radiat Prot Dosimetry 100:369-72. 2002
    ..The relative intensities of the emission bands do. however, change as a function of readout temperature and dose, a behaviour that could be connected to a temperature and dose dependent perturbation between spatially coupled TCs and LCs...
  88. ncbi TL emission spectra from differently doped LiF:Mg detectors
    E Mandowska
    Institute of Physics Pedagogical University, Armi Krajowej, Czestochowa, Poland
    Radiat Prot Dosimetry 100:451-4. 2002
    ..Preliminary results indicate that emission of the LiF:Mg,Cu,Ti sample is similar to that of LiF:Mg,Cu,P rather than to LiF:Mg,Ti, showing a maximum for wavelengths well below 400 nm...
  89. ncbi The effects of ionisation density on the thermoluminescence response (efficiency) of LiF:Mg,Ti and LiF:Mg,Cu,P
    Yigal Horowitz
    Physics Department, Ben Gurion University of the Negev, Beersheva, Israel
    Radiat Prot Dosimetry 109:331-48. 2004
    ....
  90. ncbi On fading corrections for LiF:Mg,Ti irradiated by thermal neutrons
    U German
    NRC Negev, P O Box 9001, Beer Sheva 84190, Israel
    Radiat Prot Dosimetry 110:305-8. 2004
    ..Thus, by employing the ROI method, a fading independent evaluation of the thermal neutron dose can be made...
  91. ncbi Reproducibility of TL measurements in a mixed field of thermal neutrons and photons
    A C Fernandes
    Portuguese Research Reactor, Nuclear and Technological Institute, Sacavem
    Radiat Prot Dosimetry 101:481-4. 2002
    ..GR-100 sensitivity decreased after mixed-field irradiations, while no significant change was found for the other materials. Using GR-100 for the dosimetry of mixed and high-intensity fields requires careful procedures...
  92. ncbi Thermoluminescence dosimetric properties of a new thin beta detector (LiF:Mg, Cu, P; GR-200F) in comparison with highly sensitive Al2O3:C beta dosimeters
    N A El-Faramawy
    GSF National Research Centre for Environment and Health, Institute for Radiation Protection, D 85758 Neuherberg, Germany
    J Radiol Prot 24:273-82. 2004
    ..The photon energy responses of the detectors are investigated using 150 keV filtered x-rays and 60Co gamma-rays...
  93. ncbi Measurements of the optical density and the thermoluminescent response of LiF:Mg,Ti exposed to high doses of 60Co gamma rays
    C Montaño-García
    Facultad de Ciencias, UNAM, A P 70 842, 04510 Mexico, DF, Mexico
    Radiat Prot Dosimetry 119:230-2. 2006
    ..0 x 10(-5) Gy(-1). Once the absorption spectra were obtained, the glow curves and the TL response were obtained. In the dose range, 290-10,000 Gy, the TL response of peaks 5 and 7 was supralinear-sublinear...
  94. ncbi Energy response of LiF and Mg2SiO4 TLDs to 10-150 keV monoenergetic photons
    A Konnai
    National Maritime Research Institute, Shinkawa 6 38 1, Mitaka, Tokyo 181 0004, Japan
    Radiat Prot Dosimetry 115:334-6. 2005
    ..The Mg2SiO4:Tb response was nearly bone equivalent. Linearity of dose responses was also confirmed up to 2 Gy on each TL material...
  95. ncbi On the roles of the dopants in LiF: Mg,Cu,Na,Si thermoluminescent material
    J I Lee
    Health Physics Department, Korea Atomic Energy Research Institute, PO Box 105 Yuseong, Daejeon, Korea
    Radiat Prot Dosimetry 115:340-4. 2005
    ..It is considered that Na and Si each plays a role in the improvement of the luminescence efficiency...
  96. ncbi LiF:Mg,Cu,P glow curve shape dependence on heating rate
    L Z Luo
    Thermo Electron Corporation, 26400 Broadway Avenue, Oakwood Village, OH 44146, USA
    Radiat Prot Dosimetry 119:184-90. 2006
    ..The curves are deconvoluted using the new Harshaw Glow Curve Analyser (GCA) program. Results of the study are presented, as well as possible explanations as to the observed effects...
  97. ncbi The dose-response of Harshaw TLD-700H
    K J Velbeck
    Thermo Electron Corporation, 26400 Broadway Avenue, Oakwood Village, OH 44146 USA
    Radiat Prot Dosimetry 119:255-8. 2006
    ..The simple glow curve structure provides insignificant fade, eliminating special oven preparation methods experienced by other materials. The work presented in this paper quantifies the performance of Harshaw TLD-700H in extended ranges...
  98. ncbi Optical excitation of LiF:Mg,Ti following alpha and beta irradiation
    Y S Horowitz
    Physics Department, Ben Gurion University, Beer Sheva 84105, Israel
    Radiat Prot Dosimetry 119:386-9. 2006
    ....
  99. ncbi Analysis of spectrally resolved thermoluminescence of LiF:Mg,Cu,P detectors by the surface fitting method using algorithm for unrestricted peak positions
    Ewa Mandowska
    Institute of Physics, JD University, ul Armii Krajowej 13 15, Pl 42 200 Czestochowa, Poland
    Radiat Prot Dosimetry 119:89-92. 2006
    ..The spectra were analysed using two different variants of surface fitting--for restricted and unrestricted peak positions...
  100. ncbi Tissue-equivalent TL sheet dosimetry system for X- and gamma-ray dose mapping
    N Nariyama
    Japan Synchrotron Radiation Research Institute, Mikazuki, Sayo, Hyogo 679 5198, Japan
    Radiat Prot Dosimetry 120:136-9. 2006
    ..Irradiation using synchrotron radiation between 10 and 100 keV and (60)Co gamma rays showed that the TL sheet dosimetry system was promising for radiation dose mapping for various purposes...
  101. ncbi Energy response of a two-dimensional sheet-type LiF:Mg,Cu,P TL dosemeter to photons
    Akiko Konnai
    National Maritime Research Institute, Mitaka, Tokyo 181 0004, Japan
    Radiat Prot Dosimetry 120:125-8. 2006
    ..Therefore the NTL sheet can be said to have excellent properties for dose measurements...

Research Grants62

  1. Antidepressant discontinuation effects
    Ross Baldessarini; Fiscal Year: 2007
    ..bipolar depressive subjects separately. The findings expected should contribute to improved safety of antidepressant treatment and reduced morbid and mortal risks following its discontinuation. [unreadable] [unreadable]..
  2. Course and Morbidity in Bipolar I Disorder
    Ross Baldessarini; Fiscal Year: 2006
    ..Anticipated findings should contribute important new information to guide effective interventions and allocation of increasingly limited treatment resources for BPD patients. ..
  3. Chamomile therapy for generalized anxiety disorder
    Jay Amsterdam; Fiscal Year: 2006
    ....
  4. SPECT Brain Imaging as a Biomarker of Major Depression
    Jay Amsterdam; Fiscal Year: 2007
    ..We will compare these results to measurements of striatal DAT levels in 22 non-depressed, healthy subjects studied under similar conditions with [99mTc]TRODAT-1 SPECT on two separate occasions 8 weeks apart. ..
  5. Black cohosh therapy for menopause-related anxiety
    Jay Amsterdam; Fiscal Year: 2006
    ..We hypothesize that Black Cohosh will result in superior QOL measures compared to placebo. ..
  6. ASYMMETRIC SYNTHESIS OF IONOPHORE/MACROLIDE ANTIBIOTICS
    David Evans; Fiscal Year: 2005
    ..Our goal has been to set in place all of the reactions necessary for the rapid assemblage of any polyketide target structure. ..
  7. ASYMMETRIC SYNTHESIS OF VANCOMYCIN ANTIBIOTICS
    David Evans; Fiscal Year: 2001
    ..During the course of this project we intend to confirm (correct) the absolute stereochemical assignments of the principal members of this family by total synthesis. ..
  8. Bipolar Statistical Summit:Methodologies to Advance Long Term Intervention Trials
    Charles Bowden; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  9. Synthesis of Polyketides and Terpenes
    David A Evans; Fiscal Year: 2010
    ..As a consequence, organic synthesis is a critical discipline that continues to have an important impact on the fields of both medicine and biology. ..
  10. NEW DEVELOPMENTS IN ORGANOCOPPER CHEMISTRY
    R Dieter; Fiscal Year: 2004
    ..The proposed synthetic routes to pyrrolidine aza sugars will develop the potential synthetic power of alpha-aminoalkylcuprate chemistry. ..
  11. Bipolar II Depression: Lithium, SSRI or the Combination
    Susan L McElroy; Fiscal Year: 2010
    ..We also hypothesize that the frequency of side effects will be significantly less in patients on SSRI monotherapy. Thus, secondary aims include assessment of patient satisfaction, which may affect compliance in the clinical setting. ..
  12. Divalproex and Placebo, Lithium, or Quetiapine for Mania
    Trisha Suppes; Fiscal Year: 2008
    ..abstract_text> ..
  13. Acute Treatment of Bipolar II Depression
    PATRICIA SUPPES; Fiscal Year: 2005
    ..This pilot study will provide data addressing the aims and sample size needed for a full-scale intervention trial. ..
  14. ADJUNCTIVE ACUPUNCTURE TO TREAT BIPOLAR DEPRESSION
    PATRICIA SUPPES; Fiscal Year: 2002
    ..Should acupuncture demonstrate efficacy in the treatment of bipolar disorder, further studies will be proposed to evaluate its utility for maintenance and prevention. ..
  15. Bipolar Disorder, Subjectivity and Treatment Adherence
    Martha Sajatovic; Fiscal Year: 2007
    ..abstract_text> ..
  16. Prenatal Virally Induced Brain Disorder in Mouse
    SEYYED FATEMI; Fiscal Year: 2009
    ..In addition, it is expected that the results will provide clues that will lead to fundamental advances in our knowledge of the pathogenesis of schizophrenia and, therefore, of how it can be prevented and treated. ..
  17. SNP-based lithium treatment outcome diagnostic
    Troy Bremer; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  18. Antidepressant Treatment and Suicidality: Biostatistical/Methodological Solutions
    Robert Gibbons; Fiscal Year: 2006
    ..Collaboration with members of the VA (Cunningham, Valenstein), Kaiser Permanente (Clarke, Gullion), PHARMO (Erkens) and the Indian Health Service (Perez) is an integral part of the proposal. [unreadable] [unreadable] [unreadable]..
  19. Angiogenesis in hyperoxic lung fibrosis
    Ivor Douglas; Fiscal Year: 2007
    ..Columbia University has an established record of successful mentorship and training for K08 Career awardees in their preparation for careers as independent. ..
  20. Comparative Effectiveness Study for Bipolar Disorder
    Andrew A Nierenberg; Fiscal Year: 2010
    ..The two treatments will be the second generation antipsychotic mood stabilizer quetiapine and the classic mood stabilizer lithium. In addition to quetiapine or lithium, participants can be treated with other medications as needed. ..
  21. Greater New York Autism Research Center of Excellence
    Joseph Buxbaum; Fiscal Year: 2007
    ..Core B: Clinical Core; Core C: Data Management and Statistics Core; Core D: Information Transfer Core. ..
  22. Varenicline and Smoking Cessation in Schizophrenia
    SEYYED HOSSEIN FATEMI; Fiscal Year: 2010
    ..Such outcomes will be significant, because they will offer a new treatment for smoking cessation in this vulnerable population. ..
  23. S-Adenosyl Methionine(SAMe)Augmentation of SSRIs in MDD
    George Papakostas; Fiscal Year: 2008
    ..It is hoped that this project award will provide the critical fund of basic knowledge and practical experience necessary to aid the candidate in becoming an independent investigator in this area. ..
  24. Training in Psychopharmacology and Outcomes Research
    Eric Hollander; Fiscal Year: 2008
    ..of Medicine of Medicine of Medicine of Medicine of Medicine of Medicine format shown below. Role on ..
  25. FLUOXETINE IN PEDIATRIC BODY DYSMORPHIC DISORDER
    Eric Hollander; Fiscal Year: 2008
    ..Abstract Not Provided. ..
  26. Extracellular matrix abnormalities in the medial temporal lobe of subjects with s
    Sabina Berretta; Fiscal Year: 2008
    ..The proposed studies will provide potentially critical information needed to improve our understanding of these two disorders and their pharmacological treatment. [unreadable] [unreadable] [unreadable]..
  27. Psychiatric Morbidity Late Post Heart Transplant
    Mary Amanda Dew; Fiscal Year: 2008
    ..Data collection will involve semi-structured interviews, Txp Program staff evaluations, and medical record reviews. ..
  28. REVAMP Follow-Up Study
    Martin Keller; Fiscal Year: 2008
    ....
  29. New Methods for the Synthesis of Neurological Agents
    LARRY OVERMAN; Fiscal Year: 2008
    ..oryzae at 90 nM, suggesting potential antitumor activity. Because of the scarcity of these natural products from their natural sources, little biological evaluation has been carried out. ..
  30. ECT IN CLOZAPINE REFRACTORY SCHIZOPHRENIA
    Georgios Petrides; Fiscal Year: 2003
    ..The results of the study will guide clinicians faced with the problem of how to treat patients who have not been helped by standard antipsychotic medications and do not show an adequate response to clozapine. ..
  31. COLLABORATIVE DEPRESSION STUDY
    William Coryell; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  32. COLLABORATIVE DEPRESSION STUDY
    Martin Keller; Fiscal Year: 2008
    ..abstract_text> ..
  33. 'Partial' Rodent Model for GABA Defect in Schizophrenia
    Sabina Berretta; Fiscal Year: 2008
    ..The significance of these studies resides in their potential of providing functional links between neurochemical abnormalities in schizophrenia detected in interconnected limbic brain regions. ..
  34. Glycine Transport Inhibition for Nicotine Dependence in Schizophrenia
    A Evins; Fiscal Year: 2009
    ....
  35. Genetics of Early-Onset Depression
    William Coryell; Fiscal Year: 2008
    ..abstract_text> ..
  36. Neurophysiology of Working Memory in Bipolar Disorder
    Caleb Adler; Fiscal Year: 2007
    ..abstract_text> ..
  37. A COLLABORATIVE GENOMIC STUDY OF BIPOLAR DISORDER
    William Coryell; Fiscal Year: 2007
    ..Analysis of the existing sib pair families plus this large set of cases and controls should permit the confirmation of several vulnerability genes during this grant period. ..
  38. CONTROLLED-RELEASE SEALANT TO PREVENT SECONDARY CARIES
    Kenneth Anusavice; Fiscal Year: 2004
    ..mutans, site specific levels of S. mutans at the margins of amalgam and composite restorations, and the width of marginal crevices adjacent to amalgam and composite restorations). ..
  39. Mixed-Effects ZIP Models--Mental Health Service Research
    Robert Gibbons; Fiscal Year: 2004
    ..abstract_text> ..
  40. Antipsychotic use in children and adolescents
    NIKESH PATEL; Fiscal Year: 2004
    ..These analyses will examine total antipsychotic, typical antipsychotic, and atypical antipsychotic Medicaid expenditures. ..
  41. Selegiline, Oxidative Stress and MRS in HIV Dementia
    Giovanni Schifitto; Fiscal Year: 2003
    ..The proposed study will take advantage of the ACTG supporting A5090 study and of the existing MRS consortium infrastructure that will allow us to perform multicenter MRS studies. ..
  42. MAJOR DEPRESSION, ANXIETY, AND LUNG TRANSPLANTATION
    Mary Amanda Dew; Fiscal Year: 2003
    ..An ultimate aim of the analyses is to refine hypotheses about the predictive sequence of effects under investigation and thereby to revise the study's conceptual model for subsequent intervention efforts. ..
  43. Methyl Mercury Evaluation in Dental Waste Water
    James Drummond; Fiscal Year: 2003
    ..Hypothesis: Element mercury released in DWW is converted to Hg(lI) and then in more limited amounts to methyl-mercury by specific biofilm bacterial species in the Dental sewage pipes. ..
  44. Amygdalar and Thalamic Abnormalities in Schizophrenia
    Sabina Berretta; Fiscal Year: 2002
    ....
  45. TRAIT MARKER FOR PANIC DISORDER
    William Coryell; Fiscal Year: 2001
    ..If the study's predictions are sustained, subsequent efforts will be directed toward lengthening the follow-up period and toward an eventual, ten-year diagnostic reassessment. ..
  46. FAMILY PSYCHOPATHOLOGY IN CHILD BIPOLARITY
    Barbara Geller; Fiscal Year: 2004
    ..Establishing high familial aggregation of bipolar disorders in relatives of PEA-BP probands will provide the basis for future genetic and genetic-environment interaction studies. ..
  47. HIPPOCAMPAL FUNCTION DURING CORTICOSTEROID THERAPY
    E Sherwood Brown; Fiscal Year: 2004
    ..Through this award, the Pl will extend his previous research experience by adding new skills and knowledge which will be used for investigations at the interface of neuroscience and clinical research. ..
  48. BENZANNULATION APPROACH TO BIARYL ETHERS
    Michael Harmata; Fiscal Year: 2001
    ..abstract_text> ..
  49. Naltrexone for Bipolar Disorder and Alcohol Dependence
    E Sherwood Brown; Fiscal Year: 2006
    ..Alcohol use is the primary outcome, and alcohol craving is the secondary outcome. Manic and depressive symptom severity and the relationship between changes in alcohol use and changes in mood will be expIored. ..
  50. COMPARING THREE ELECTRODE PLACEMENTS TO OPTIMIZE ECT
    Georgios Petrides; Fiscal Year: 2005
    ..The results of this study will promote more effective and safer treatment of the most severely ill depressed patients. ..
  51. Treating Depressed Mothers in a Community Clinic
    Holly Swartz; Fiscal Year: 2006
    ..The skills, training, and pilot data obtained from this award will subsequently support the Candidate's development of an R01 application in Years 03-05 of the award period. ..
  52. Postpartum Depression: Omega-3 FA vs Placebo
    Marlene Freeman; Fiscal Year: 2006
    ..These doses should provide an adequate test of the efficacy of omega-3 fatty acids while being safe for the mother and breastfeeding baby. ..
  53. Long-term antidepressant outcome in bipolar depression
    NASSIR GHAEMI; Fiscal Year: 2005
    ..In this process, the applicant will develop competence to lead independent studies of the long-term treatment of bipolar disorder as a principal investigator. ..
  54. FAILURE ANALYSIS OF DENTAL RESTORATIONS
    Janet Quinn; Fiscal Year: 2005
    ..abstract_text> ..
  55. Cardiac Teratogenicity of Lithium
    Kersti Linask; Fiscal Year: 2004
    ..Until the safety of lithium is conclusively proven, one must assume teratogenic potential and harm to the fetus. ..
  56. Pharmacotherapy for Minor Depression
    Andrew Nierenberg; Fiscal Year: 2004
    ..The results of this study will have profound public health implications by improving our understanding of the efficacy of SJW and standard antidepressants for the treatment of MinorD. ..
  57. PHARMACOTHERAPY OF ADOLESCENT BODY DYSMORPHIC DISORDER
    Eric Hollander; Fiscal Year: 2002
    ..When untreated, adolescent-onset BDD appears to often interfere with the developmental tasks of adolescence, to persist, and to cause substantial morbidity through out the life span. ..
  58. Divalproex Sodium/Placebo In Child/Adolesent Autism
    Eric Hollander; Fiscal Year: 2003
    ....
  59. COMPARING THREE ELECTRODE PLACEMENTS TO OPTIMIZE ECT
    Keith Rasmussen; Fiscal Year: 2005
    ..The results of this study will promote more effective and safer treatment of the most severely ill depressed patients. ..
  60. Treating Asthma Patients with Major Depressive Disorder
    E Sherwood Brown; Fiscal Year: 2004
    ....
  61. Sensory Gating in Schizophrenia: Multiple Measures
    Julie Patterson; Fiscal Year: 2004
    ....